HEADER TRANSFERASE/TRANSFERASE INHIBITOR 07-APR-18 6CZ4 TITLE STRUCTURE OF THE PTK6 KINASE DOMAIN BOUND TO A TYPE II INHIBITOR 2- TITLE 2 {[(3R,4S)-3-FLUORO-1-{[4-(TRIFLUOROMETHOXY)PHENYL]ACETYL}PIPERIDIN-4- TITLE 3 YL]OXY}-5-(1-METHYL-1H-IMIDAZOL-4-YL)PYRIDINE-3-CARBOXAMIDE COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEIN-TYROSINE KINASE 6; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: BREAST TUMOR KINASE,TYROSINE-PROTEIN KINASE BRK; COMPND 5 EC: 2.7.10.2; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: PTK6, BRK; SOURCE 6 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7108 KEYWDS PROTEIN KINASE, PTK6, TRANSFERASE-TRANSFERASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR K.S.GAJIWALA,E.JOHNSON,C.N.CRONIN REVDAT 3 13-MAR-24 6CZ4 1 REMARK REVDAT 2 03-OCT-18 6CZ4 1 REMARK REVDAT 1 20-JUN-18 6CZ4 0 JRNL AUTH L.QIU,K.LEVINE,K.S.GAJIWALA,C.N.CRONIN,A.NAGATA,E.JOHNSON, JRNL AUTH 2 M.KRAUS,J.TATLOCK,R.KANIA,T.FOLEY,S.SUN JRNL TITL SMALL MOLECULE INHIBITORS REVEAL PTK6 KINASE IS NOT AN JRNL TITL 2 ONCOGENIC DRIVER IN BREAST CANCERS. JRNL REF PLOS ONE V. 13 98374 2018 JRNL REFN ESSN 1932-6203 JRNL PMID 29879184 JRNL DOI 10.1371/JOURNAL.PONE.0198374 REMARK 2 REMARK 2 RESOLUTION. 1.50 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNX 2005 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN,ACCELRYS REMARK 3 : SOFTWARE INC.(BADGER,BERARD,KUMAR,SZALMA, REMARK 3 : YIP,DZAKULA) REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.50 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 50.82 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 1090310.760 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 98.4 REMARK 3 NUMBER OF REFLECTIONS : 45221 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.203 REMARK 3 R VALUE (WORKING SET) : 0.203 REMARK 3 FREE R VALUE : 0.209 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.900 REMARK 3 FREE R VALUE TEST SET COUNT : 2202 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.004 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.2500 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.2540 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.210 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 4.900 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 2203 REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : 0.0040 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.50 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.59 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 90.60 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 6505 REMARK 3 BIN R VALUE (WORKING SET) : 0.2730 REMARK 3 BIN FREE R VALUE : 0.2940 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.80 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 326 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.016 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2069 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 37 REMARK 3 SOLVENT ATOMS : 180 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 24.80 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 28.70 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.70000 REMARK 3 B22 (A**2) : 6.45000 REMARK 3 B33 (A**2) : -5.75000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.18 REMARK 3 ESD FROM SIGMAA (A) : 0.15 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.19 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.17 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.004 REMARK 3 BOND ANGLES (DEGREES) : 0.800 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 19.30 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.610 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.320 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.140 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.160 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.320 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : 0.37 REMARK 3 BSOL : 43.90 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : REMARK 3 ACCELRYS_CNX:LIBRARIES/TOPPAR/PROTEIN_REP.PARA REMARK 3 PARAMETER FILE 2 : ACCELRYS_CNX:LIBRARIES/TOPPAR/DNA REMARK 3 -RNA_REP.PARA REMARK 3 PARAMETER FILE 3 : REMARK 3 ACCELRYS_CNX:LIBRARIES/TOPPAR/WATER_REP.PARAM REMARK 3 PARAMETER FILE 4 : ACCELRYS_CNX:LIBRARIES/TOPPAR/ION.PARAM REMARK 3 PARAMETER FILE 5 : LIG-EDITED.PAR REMARK 3 PARAMETER FILE 6 : NULL REMARK 3 TOPOLOGY FILE 1 : ACCELRYS_CNX:LIBRARIES/TOPPAR/PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : ACCELRYS_CNX:LIBRARIES/TOPPAR/DNA-RNA.TOP REMARK 3 TOPOLOGY FILE 3 : ACCELRYS_CNX:LIBRARIES/TOPPAR/WATER.TOP REMARK 3 TOPOLOGY FILE 4 : ACCELRYS_CNX:LIBRARIES/TOPPAR/ION.TOP REMARK 3 TOPOLOGY FILE 5 : LIG-EDITED.TOP REMARK 3 TOPOLOGY FILE 6 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 6CZ4 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 09-APR-18. REMARK 100 THE DEPOSITION ID IS D_1000233767. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 19-OCT-15 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS3 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : AIMLESS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 46820 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.480 REMARK 200 RESOLUTION RANGE LOW (A) : 50.820 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 97.9 REMARK 200 DATA REDUNDANCY : 5.900 REMARK 200 R MERGE (I) : 0.03700 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 22.9000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.48 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.56 REMARK 200 COMPLETENESS FOR SHELL (%) : 86.8 REMARK 200 DATA REDUNDANCY IN SHELL : 3.60 REMARK 200 R MERGE FOR SHELL (I) : 0.41800 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.600 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CNX REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 46.87 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.31 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 1.25 M SODIUM DIHYDROGEN PHOSPHATE, REMARK 280 0.89 M DI-POTASSIUM HYDROGEN PHOSPHATE, 0.2 M LITHIUM SULFATE, REMARK 280 0.1 M CHES, PH 9.8, 13O C, VAPOR DIFFUSION, SITTING DROP, REMARK 280 TEMPERATURE 286K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 18.95700 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 67.31450 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 27.43650 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 67.31450 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 18.95700 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 27.43650 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 180 REMARK 465 SER A 181 REMARK 465 ASP A 182 REMARK 465 ASP A 346 REMARK 465 HIS A 347 REMARK 465 ASN A 348 REMARK 465 ILE A 349 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 CYS A 194 -129.06 -106.58 REMARK 500 ASP A 212 -8.16 73.13 REMARK 500 ARG A 311 -10.26 77.78 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue FKY A 9001 DBREF 6CZ4 A 182 443 UNP Q13882 PTK6_HUMAN 182 443 SEQADV 6CZ4 GLY A 180 UNP Q13882 EXPRESSION TAG SEQADV 6CZ4 SER A 181 UNP Q13882 EXPRESSION TAG SEQADV 6CZ4 ALA A 184 UNP Q13882 TRP 184 CONFLICT SEQRES 1 A 264 GLY SER ASP ASP ALA GLU ARG PRO ARG GLU GLU PHE THR SEQRES 2 A 264 LEU CYS ARG LYS LEU GLY SER GLY TYR PHE GLY GLU VAL SEQRES 3 A 264 PHE GLU GLY LEU TRP LYS ASP ARG VAL GLN VAL ALA ILE SEQRES 4 A 264 LYS VAL ILE SER ARG ASP ASN LEU LEU HIS GLN GLN MET SEQRES 5 A 264 LEU GLN SER GLU ILE GLN ALA MET LYS LYS LEU ARG HIS SEQRES 6 A 264 LYS HIS ILE LEU ALA LEU TYR ALA VAL VAL SER VAL GLY SEQRES 7 A 264 ASP PRO VAL TYR ILE ILE THR GLU LEU MET ALA LYS GLY SEQRES 8 A 264 SER LEU LEU GLU LEU LEU ARG ASP SER ASP GLU LYS VAL SEQRES 9 A 264 LEU PRO VAL SER GLU LEU LEU ASP ILE ALA TRP GLN VAL SEQRES 10 A 264 ALA GLU GLY MET CYS TYR LEU GLU SER GLN ASN TYR ILE SEQRES 11 A 264 HIS ARG ASP LEU ALA ALA ARG ASN ILE LEU VAL GLY GLU SEQRES 12 A 264 ASN THR LEU CYS LYS VAL GLY ASP PHE GLY LEU ALA ARG SEQRES 13 A 264 LEU ILE LYS GLU ASP VAL TYR LEU SER HIS ASP HIS ASN SEQRES 14 A 264 ILE PRO TYR LYS TRP THR ALA PRO GLU ALA LEU SER ARG SEQRES 15 A 264 GLY HIS TYR SER THR LYS SER ASP VAL TRP SER PHE GLY SEQRES 16 A 264 ILE LEU LEU HIS GLU MET PHE SER ARG GLY GLN VAL PRO SEQRES 17 A 264 TYR PRO GLY MET SER ASN HIS GLU ALA PHE LEU ARG VAL SEQRES 18 A 264 ASP ALA GLY TYR ARG MET PRO CYS PRO LEU GLU CYS PRO SEQRES 19 A 264 PRO SER VAL HIS LYS LEU MET LEU THR CYS TRP CYS ARG SEQRES 20 A 264 ASP PRO GLU GLN ARG PRO CYS PHE LYS ALA LEU ARG GLU SEQRES 21 A 264 ARG LEU SER SER HET FKY A9001 37 HETNAM FKY 2-{[(3R,4S)-3-FLUORO-1-{[4-(TRIFLUOROMETHOXY) HETNAM 2 FKY PHENYL]ACETYL}PIPERIDIN-4-YL]OXY}-5-(1-METHYL-1H- HETNAM 3 FKY IMIDAZOL-4-YL)PYRIDINE-3-CARBOXAMIDE FORMUL 2 FKY C24 H23 F4 N5 O4 FORMUL 3 HOH *180(H2 O) HELIX 1 AA1 PRO A 187 GLU A 189 5 3 HELIX 2 AA2 ARG A 223 LEU A 226 5 4 HELIX 3 AA3 HIS A 228 LYS A 241 1 14 HELIX 4 AA4 LEU A 272 SER A 279 1 8 HELIX 5 AA5 PRO A 285 GLN A 306 1 22 HELIX 6 AA6 ALA A 314 ARG A 316 5 3 HELIX 7 AA7 LYS A 338 LEU A 343 1 6 HELIX 8 AA8 PRO A 350 THR A 354 5 5 HELIX 9 AA9 ALA A 355 GLY A 362 1 8 HELIX 10 AB1 SER A 365 PHE A 381 1 17 HELIX 11 AB2 SER A 392 GLY A 403 1 12 HELIX 12 AB3 PRO A 413 TRP A 424 1 12 HELIX 13 AB4 ASP A 427 ARG A 431 5 5 HELIX 14 AB5 CYS A 433 SER A 442 1 10 SHEET 1 AA1 5 PHE A 191 GLY A 200 0 SHEET 2 AA1 5 GLY A 203 TRP A 210 -1 O VAL A 205 N LEU A 197 SHEET 3 AA1 5 VAL A 214 ILE A 221 -1 O VAL A 220 N GLU A 204 SHEET 4 AA1 5 VAL A 260 THR A 264 -1 O ILE A 262 N LYS A 219 SHEET 5 AA1 5 LEU A 250 VAL A 254 -1 N ALA A 252 O ILE A 263 SHEET 1 AA2 3 GLY A 270 SER A 271 0 SHEET 2 AA2 3 ILE A 318 VAL A 320 -1 O VAL A 320 N GLY A 270 SHEET 3 AA2 3 CYS A 326 VAL A 328 -1 O LYS A 327 N LEU A 319 CISPEP 1 ASP A 258 PRO A 259 0 -6.06 SITE 1 AC1 20 LEU A 197 ALA A 217 MET A 239 LEU A 242 SITE 2 AC1 20 ILE A 247 LEU A 248 THR A 264 GLU A 265 SITE 3 AC1 20 LEU A 266 MET A 267 ALA A 268 GLY A 270 SITE 4 AC1 20 LEU A 303 TYR A 308 HIS A 310 VAL A 328 SITE 5 AC1 20 GLY A 329 ASP A 330 PHE A 331 HOH A9193 CRYST1 37.914 54.873 134.629 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.026375 0.000000 0.000000 0.00000 SCALE2 0.000000 0.018224 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007428 0.00000